NZ278018A - Producing undenatured whey protein concentrate - Google Patents
Producing undenatured whey protein concentrateInfo
- Publication number
- NZ278018A NZ278018A NZ278018A NZ27801894A NZ278018A NZ 278018 A NZ278018 A NZ 278018A NZ 278018 A NZ278018 A NZ 278018A NZ 27801894 A NZ27801894 A NZ 27801894A NZ 278018 A NZ278018 A NZ 278018A
- Authority
- NZ
- New Zealand
- Prior art keywords
- whey
- temperature
- milk
- cheese
- curd
- Prior art date
Links
- 108010046377 Whey Proteins Proteins 0.000 title claims description 76
- 102000007544 Whey Proteins Human genes 0.000 title claims description 64
- 235000021119 whey protein Nutrition 0.000 title claims description 39
- 239000012141 concentrate Substances 0.000 title claims description 32
- 238000000034 method Methods 0.000 claims description 61
- 235000013351 cheese Nutrition 0.000 claims description 50
- 235000013336 milk Nutrition 0.000 claims description 42
- 239000008267 milk Substances 0.000 claims description 42
- 210000004080 milk Anatomy 0.000 claims description 42
- 239000005862 Whey Substances 0.000 claims description 37
- 230000008569 process Effects 0.000 claims description 37
- 235000018102 proteins Nutrition 0.000 claims description 28
- 102000004169 proteins and genes Human genes 0.000 claims description 28
- 108090000623 proteins and genes Proteins 0.000 claims description 28
- 108010071390 Serum Albumin Proteins 0.000 claims description 24
- 102000007562 Serum Albumin Human genes 0.000 claims description 24
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 24
- 238000009928 pasteurization Methods 0.000 claims description 23
- 238000004519 manufacturing process Methods 0.000 claims description 20
- 239000012465 retentate Substances 0.000 claims description 20
- 238000000108 ultra-filtration Methods 0.000 claims description 15
- 229960003180 glutathione Drugs 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 238000004925 denaturation Methods 0.000 claims description 9
- 230000036425 denaturation Effects 0.000 claims description 9
- 108010024636 Glutathione Proteins 0.000 claims description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 8
- 239000008101 lactose Substances 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 6
- 230000028996 humoral immune response Effects 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 238000000926 separation method Methods 0.000 claims description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 5
- PABVKUJVLNMOJP-WHFBIAKZSA-N Glu-Cys Chemical group OC(=O)CC[C@H](N)C(=O)N[C@@H](CS)C(O)=O PABVKUJVLNMOJP-WHFBIAKZSA-N 0.000 claims description 5
- 229940098773 bovine serum albumin Drugs 0.000 claims description 5
- 230000009885 systemic effect Effects 0.000 claims description 5
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000006227 byproduct Substances 0.000 claims description 4
- 229910001424 calcium ion Inorganic materials 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 230000001093 anti-cancer Effects 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 230000003834 intracellular effect Effects 0.000 claims description 3
- 238000003825 pressing Methods 0.000 claims description 3
- 238000007493 shaping process Methods 0.000 claims description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 2
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims description 2
- 102000010445 Lactoferrin Human genes 0.000 claims description 2
- 108010063045 Lactoferrin Proteins 0.000 claims description 2
- 239000001110 calcium chloride Substances 0.000 claims description 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 2
- 229960003067 cystine Drugs 0.000 claims description 2
- 238000011026 diafiltration Methods 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 229940043430 calcium compound Drugs 0.000 claims 1
- 150000001674 calcium compounds Chemical class 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 239000012263 liquid product Substances 0.000 claims 1
- 241000894006 Bacteria Species 0.000 description 11
- 102000011632 Caseins Human genes 0.000 description 10
- 108010076119 Caseins Proteins 0.000 description 10
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 9
- 235000021240 caseins Nutrition 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 239000005018 casein Substances 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 239000012528 membrane Substances 0.000 description 7
- 235000013365 dairy product Nutrition 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 108010058314 rennet Proteins 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 229940108461 rennet Drugs 0.000 description 5
- 238000010411 cooking Methods 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 230000004907 flux Effects 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 3
- 230000037358 bacterial metabolism Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000000693 micelle Substances 0.000 description 3
- 235000020185 raw untreated milk Nutrition 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 102000004407 Lactalbumin Human genes 0.000 description 2
- 108090000942 Lactalbumin Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002766 immunoenhancing effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000001471 micro-filtration Methods 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- RHUYHJGZWVXEHW-UHFFFAOYSA-N 1,1-Dimethyhydrazine Chemical compound CN(C)N RHUYHJGZWVXEHW-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 101710173438 Late L2 mu core protein Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000035109 Pneumococcal Infections Diseases 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010039438 Salmonella Infections Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960001506 brilliant green Drugs 0.000 description 1
- HXCILVUBKWANLN-UHFFFAOYSA-N brilliant green cation Chemical compound C1=CC(N(CC)CC)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](CC)CC)C=C1 HXCILVUBKWANLN-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 229940021722 caseins Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039447 salmonellosis Diseases 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000003403 water pollutant Substances 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
- 235000021246 κ-casein Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
- A23J1/205—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey from whey, e.g. lactalbumine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C19/00—Cheese; Cheese preparations; Making thereof
- A23C19/02—Making cheese curd
- A23C19/05—Treating milk before coagulation; Separating whey from curd
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/14—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
- A23C9/142—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration
- A23C9/1425—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration by ultrafiltration, microfiltration or diafiltration of whey, e.g. treatment of the UF permeate
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Water Supply & Treatment (AREA)
- Dairy Products (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
New Zealand No. 278018 Intemationrr' No. PCT/CA94/007z6
TO BE ENTERED AFTER ACCEPTANCE AND PUBLICATION
Priority dates: 30.12.1993;30.09.1994;
Complete Specification Filed: 23.12.1994
Classification: (6) A23J1/20; A23C19/05; A23C9/14; A23C21/00; A23L1/305
Publication date: 27 April 1998
Journal No.: 1427
NEW ZEALAND PATENTS ACT 1953
COMPLETE SPECIFICATION
Title of Invention:
Process for making undenatured whey protein concentrate
Name, address and nationality of applicant(s) as in international application form:
IMMUNOTEC RESEARCH CORPORATION LTD, Suite 1100, 2075 rue University, Montreal, Quebec H3A 2L1, Canada
*
2
WO 95/17830 PCT/CA94/00726
78
PROCESS FOR MAKING UNDENATURED WHEY PROTEIN CONCENTRATE
This invention relates to an improved process for producing a whey protein concentrate having a serum albumin content of about 9% or more. 5 Related Applications
This application is a continuation-in-part of U.S. serial number 08/175,637 filed December 30, 1993 which is a continuation in part of U.S. Serial Number 07/989,186 filed December 11, 1992. The contents of such applications are hereby incorporated by reference in their entirety. 10 Background of the Invention and Objectives
As early as 1982 Bounous et al (1) showed that dietary whey protein concentrate (WPC) improved the active systemic humoral immune response in a mammal, as measured by sheep red blood cell injections. It was however found that the use of high temperature pasteurization of milk [in 1988 and 15 subsequent years following a Salmonellosis epidemic in Europe] greatly reduced the effectiveness of commercially available whey protein concentrates in improving the immune response.
United States Patent 5,230,902 dated July 27, 1993 described a method of improving the humoral immune response or increasing the concentration 20 levels of glutathione in mammals, comprising administering orally to a mammal a therapeutically or prophylactically effective amount of undenatured whey protein concentrate. U.S. Application 989,186 filed December 11, 1992 as a continuation in part of previous related U.S. applications provided an improved method for making undenatured whey protein concentrate. 25 In said related applications the discovery that undenatured whey protein concentrate had an enhanced immunological effect was presented. It was furthermore explained that in the conventional high temperature treatment of milk the thermosensitive protein serum albumin were partially heat denatured and hence precipitated in the curd. Said related applications describe 30 experiments where WPC was prepared using the lowest level of heat treatment of milk compatible with safety standards, so as to obtain a whey protein distribution having a high content of the thermolabile serum albumin. It was
1
2 7 t> 0 1 8
found that the presence of the 6 glutamylcysceine (Glu-Cys) group/molecule in the serum albumin (BSA) and the specific intramolecular disulfide bond of cystine related to the undenatured conformation of the molecule, were a key factor in the glutathione (GSH) promoting activity of WPC (enhancement of GSH levels in tissues). They are believed to represent the common denominator underlying the beneficial effect of WPC (2,3).
Dietary W.P.C. produced with lower levels of heat treatment improves systemic humoral immune response, increases the resistance of target cells against the effect of carcinogens including chemical carcinogens such as dimethylhydrazine, improves'resistance to pneumococcal infection, and provides a sustained increase of tissue (intracellular) glutathione.
The object of this invention is to provide an improved process for preparing a whey protein concentrate that has adequately low bacterial levels without excessive levels of protein denaturation. It is a particular object to provide a process that will achieve a whey protein concentrate having a serum albumin of about 9% and adequate bacterial reduction. This approximately 9% level of serum albumin was found in our studies to be important for the achievement of sustained increase of tissue glutathione for the properties such as improved systemic humoral immune response described above (References 2 and 3).
It is a further object to provide a process that will achieve a whey protein concentrate having not only a high serum albumin content but also a high content of other Glu-Cys containing proteins or Glutathione homologues such as (Glu-Cys-Ala). The use of process conditions to give a high serum albumin content will also give a high content of such other Glu-Cys containing proteins.
Serum albumin is the most easily denatured serum protein since its denaturation is not as reversible as that of alpha-lactalbumin (4). It therefore is a further object of this invention to maintain rigorous control of temperature and other conditions to minimize denaturation of serum albumin.
The casein in raw milk occurs in the form of a colloidal dispersion. The particles of this dispersion range from 20 to 200 nm (nanonjj^5i&prJ,p^ office
0 9 FFR 1998
2
of New Zealand
WO 95/17830 PCT/CA94/00726
diameter and are generally referred to as casein micelles.
The industrial methods of separation of the casein are based on the destabilization of these proteins either by lowering the pH of milk to the isoelectric point (pH 4.6) at 20°C or by enzymatic (rennet) hydrolysis of the 5 Kappa casein which stabilizes the micelles.
The first procedure is not suitable for the recovery of native whey proteins since low pH has been shown to denature Bovine serum albumin, apparently because of repulsion of acidic amino acids (Haurowitz, 1963) (11). Furthermore, if excessively high temperatures are used in this procedure, 10 there would be a considerable increase in the denaturing effect of a low pH.
The second procedure is less economically feasible because the caseins recovered are less functional for dairy industry use.
Considering those facts and other economical aspects, our objective is to develop a combination of method "steps which are compatible with cheese 15 making. The cheese represents roughly 10% (by weight) of milk being treated and the whey represents approximately 90%, of which 0.6 to 0.7% consists of whey proteins.
A recent study (5) has shown that a microfiltration membrane containing pores with average diameter of 0.2 micron will selectively retain 20 the casein micelles from skim milk. However, that study concentrated on the separation of casein.
The Invention
We propose to utilize low temperature lenient techniques to achieve the objectives of this invention.
In accordance with this invention a process is provided for producing an undenatured whey protein concentrate having a serum albumin content of about 9% or more as a by-product of a process for making cheese, preferably cheddar cheese, comprising:
(1) cold standardization of the fat content in milk at a temperature 30 not greater than about 4°C. By this approach we reduce the outgrowth of bacteria; furthermore this method reduces fat losses and breakdown of fat globules which would lead to further reactions involving enzymes and
3
278 0 i
8 „
bacterial metabolism;
(2) pasteurization under conditions that will avoid any substantial denaturing of the protein in the milk;
(3) chilling preliminary to cheese production to a temperature of about 30°C.
(4) making curd and whey at a temperature not greater than about
40°C;
(5) separating the curd from the whey;
(6) removing excess fat from the whey;
(7) pasteurization, if needed, at a high temperature for a time short enough to avoid denaturing of most of the protein in the whey;
(8) ultrafiltration at a temperature close to but not substantially in excess of 40°C. to provide a retentate; which may provide an end product in liquid form.
(9) where a dry powder is desired, drying said retentate, preferably by freeze drying at a temperature and for a time that will not denature the protein.
The pH is maintained at not less than 6 throughout steps 1 to 8.
The invention provides a process for producing an undenatured whey protein concentrate having a serum albumin content of about 9% or more as a by-product of a process for making cheese comprising the following steps:
(1) cold standardization of the fat content in milk;
(2) pasteurization prior to cheese making under conditions that will avoid any substantial denaturing of the protein in the milk;
(3) chilling preliminary to cheese production without the addition of calcium ions, to a temperature of about 30°C;
(4) making cheese curd and whey at a temperature not greater than about 40°C; RECEIVED
Intellectual Property Office
♦•A a. -tii u 0 -9 FFR 1S98
(5) separating the curd from the whey;
of New Zealand
4 (followed by paae 4a)
2780 1$
(6) removal of excess fat from the whey;
(7) pasteurization, if needed, at a high temperature for a time short enough to avoid any substantial denaturing of the protein in the milk;
(8) ultrafiltration at a temperature close to but not substantially in excess of 40°C to provide a retentate;
the pH being maintained at not less than 6 through steps (1) to (8).
The invention also provides a process for producing an undenatured whey protein concentrate, which concentrate contains substantially all thermolabile whey proteins of the source milk with glutamylcysteine groups and disulfide bonds, in an amount effective to replenish depleted intracellular glutathione, enhance systemic humoral immune response and exert anti-cancer effects, comprising cold standardization of milk, pasteurization, the formation of curd and whey, separation of the whey, filtering concentrating and drying the whey under conditions of time and temperature that will avoid substantial loss of said glutamylcysteine groups and at a pH of not less than 6 prior to concentration.
Brief description of the drawing rigure 1 is a schematic representation of the process of this invention for producing a whey protein concentrate with immunoenhancing properties.
Detailed description of the invention
Materia] and Methods
Individual whey proteins were measured by polyacrylamide gel electrophoresis. Samples of concentrated whey were applied on 16%
polyacrylamide at pH 8 (Laemmli- buffer-system) after the samples were reduced with 10% 2-mercaptoethanol. Samples were applied so that each slot received 10-20 fig (micrograms) of protein. Electrophoresis was performed at 200 volts for 70 minutes. The results were also confirmed by chromatography. RB6E1VED ce
Extent of protein denaturation by the process was determinJJd'M^"' 'rop8rty triplicate by the nitrogen solubility index (NSI) at pH 4.6 and 3000 g.^ ^
of New Ze»^nd
4a
(followed by page 5)
WO 95/17830 PCT/CA94/00726
0
(Association of Official Analytical Chemists (AOAC) 1985 ref. 6). The method utilized in these experiments differs from that described in Reference 2 and represents a more accurate reflection of the undenatured state of protein.
Protein content (N X 6.38) and total lipids of samples were determined in duplicate respectively by the standard method of Kjeldahl and the method of Mojonnier.
Moisture content was determined in duplicate by AOAC method (7).
Total coliforms count was determined following incubation at 37°C for 10 18 h in brilliant green using the most probable number method. Total bacteria count (aerobic mesophiles) was determined following incubation at 32 °C for 48 h in PCA medium. Both methods are approved by the International Dairy Federation and American Public Health Association.
Lactose was measured by the enzymatic method. 15 Standardization
Referring now to Figure 1, the first step is the standardization of the milk. This involves skimming the milk to a desired fat content. This procedure is used for two reasons. The first is to attain the legal percentage of fat on a dry basis of the final cheese. The second is to achieve the best 20 yield and quality (body and texture) of cheese.
For cheddar cheese the optimum fat to casein ratio in milk is one part fat to 0.7 part of casein (Kosikowski)(9).
The usual practice has been to use a temperature in the range of 50°C to 65°C as this is the most efficient range for skimming to a level of 0.05% 25 of fat. However, we prefer in accordance with this invention to maintain the temperature at a lower level, preferably not greater than about 4°C. This low temperature during the fat removal process is necessary to avoid oxidation of lipids which would then tend to continue over time during storage and produce rancidity (liberation of fatty acids) which could in turn damage the 30 conformation without affecting nutritional efficiency of the labile proteins.
The raw milk used in the examples had the following composition:
Composition
PCT/CA9-4/00726
% protein 3.2 % fat 3.65 % lactose 4.7
The pH of the composition was 6.65.
In the examples described in this application standardization of milk was carried out with a cold separator (Alfa Laval, CMRPX 714-HGV)
coupled with an automatic standardizer (Alfa Laval, Alfast Model 110). All standardization steps were carried out at 4°C. (Figure 1) and for all examples the fat content was adjusted to 3.58% of total milk.
The fat content of 3.58% was in accordance with standardization according to the following calculation:
% fat = % protein X 1.12
(in final product) (in raw milk)
% fiat = 3.2X1.12
PASTEURIZATION
The next step according to Figure 1 is pasteurization. In the examples in this application pasteurization of the milk was achieved on a heat exchanger type HTST (Alfa Laval H-10) being set at 72.6°C with a retention time of 16 sec., followed by flash cooling to 30°C.
Most countries do not allow the production of dairy products without pasteurization. Different types of pasteurization can be used:
HTST high temperature short time - 72.8°C, 16 sec.
LTLT low temperature long time - 65.6°C, 30 min.
UHT ultra high temperature - 120°C for a few seconds;
but the effect on denaturation of protein and especially serum albumin are mostly evident with LTLT and UHT.
The introduction of high temperature pasteurization of milk was prompted by two different objectives. The first was to obtain a near sterilization of milk following the cheese related infection diseases reported
during 1988 in Europe. The second objective was to improve the yield during cheese making.
In fact, cheese makers have noticed that at these temperatures, or
6
WO 95/17830 PCT/CA94/00726
increasing by five degrees or less above pasteurizing temperature, yield could be increased in certain types of cheese.
In accordance with the teaching of this invention ultra high temperatures should be avoided, contrary to present practice. Long time 5 exposure to a lowest temperature of the order of 65.6°C should also be avoided. Even a temperature as low as 55 °C causes unfolding of the bovine serum albumin molecule over a period of time (Wong & Call. 1988).
However, this invention may use high temperatures in the range 63 °C to 75 CC and preferably about 72 °C for a short time up to about 20 seconds. 10 The conditions such as time and temperature must avoid denaturing of the protein in the milk, particularly the heat labile serum albumin, and other Glu-Cys containing proteins, however such conditions of pasteurization should be such that pathogens are killed or reduced to sa acceptable level.
Cheese Production - Temperature Reduction 15 The next step according to Figure 1 is cheese production.
The preliminary step in cheese production is to reduce the temperature. In accordance with the examples of this invention the temperature is accordingly immediately reduced, such as by flash cooling to a temperature of 30°C for cheese making.
Cheese nrodactiou-addition of cultures
Since cheese making is a fermentation process, we add lactic acid cultures. Those cultures and their metabolites are mainly responsible for the acidification and repining of cheese. For Cheddar cheese we use a commercial culture of mesophilic organisms which in our examples are provided by CH. 25 Hansen Laboratory. Suitable cultures are readily available from other sources such as Miles Laboratory. The amount of cultures that has been added was 1 % of total milk being transformed in cheddar.
These cultures are added after chilling to about 30°C, which allows the necessary growth of mesophilic lactic acid bacteria for cheese making. The 30 activity of these bacteria will be controlled in such a way that the pH of the milk will never drop below pH6. Since bacteria are living organisms their rate of metabolism may vary. If it is too rapid the amount of bacteria added
7
WO 95/17830 PCT/CA94/00726
to the nnilk can be reduced, eg. from 1% of total milk to 0.75%. With less bacteria less acid is produced.
Another way of controlling the rate of metabolism is to reduce the fermentation temperature. A reduction of 2°C will normally be used for this 5 purpose.
At this preliminary stage of cheese making calcium chloride is usually added to milk to increase the firmness of the curd during the manufacture of cheese. The net result is an increase in cheese yield due to better precipitation and less losses of cheese curd particles in the whey. However, we have found 10 that denaturation of BSA is enhanced by the presence of calcium ions.
Therefore we avoid the addition of calcium ions, contrary to normal practice in cheese manufacture. Reference is also made to the report of Shimada & Matsushita 1981 (8).
Additives of this sort are avoided during production of cheese if the 15 whey generated is being used for this invention. Yield can also be increased in conventional practice by the addition of milk derivatives (casein, whey protein) to milk being transformed into cheese. This procedure is generally avoided by us because it influences the quality of the protein content of the whey. The various fraction found in normal whey will be modified resulting 20 in a whey protein concentrate having less undenatured bovine serum albumin per unit of total protein.
Cheese Production - fermentation
The fermentation period (repining period) was 1.5 hour for our examples at a temperature of 30°C. The pH decreased from 6.65 to 6.55. 25 The pH drop was thus 0.1 before rennet was added.
Cheese producing - Addition of rennet
Rennet was added at a rate of 20 ml/100 liters of milk. The time required for curd formation was 25 minutes.
The rennet used was a pure calf rennet single strength from CH. 30 Han sens Laboratory. The quantity was 20 ml./100 liters of milk. The temperature is maintained at 30°C. The rennet was diluted in 10 times its volume with water before adding to milk. The clotting time was 25 minutes.
8
WO 95/17830 PCT/CA94/00726
Cheese produc >W culturing the curd
The curd was then cut using 6 mm. cheese knives at a temperature of 30°C to provide 6 mm cubes and stirred for 15 minutes before it was cooked. Cheese production - cooking 5 In our examples the cooking period lasted 75 min and continuous agitation was used. The peak temperature of 38°C was reached in 30 minutes (1.3°C per 5 minutes). After this cooking period agitation was maintained for 1 hour.
The pH of the whey after cooking was 6.5.
It is highly desirable to avoid any cheese making steps that involves a temperature in excess of 40°C. In fact some cheese production such as Emmental requires, a temperature of more than 50°C. Raising the temperature to this level before separation of the whey and maintaining such temperature would adversely affect the serum albumin content.
Following post stirring the curd is separated from the whey.
SEPARATION OF CURD FROM WHEY
The curd should be separated from the whey at this level.
No additional whey is collected for the purposes of this invention during shaping and final pressing of the curd as acidification during this 20 period would result in a pH drop below 6.
The whey should be chilled to about 4°C as soon as it is separated from the curd if it is to be kept for more than 1/2 hour. By this procedure, the metabolism of the lactic acid bacteria is reduced and acidity does not increase. No additives (such as H^Oj) should be used as antibacterial agents. 25 Instead we use low temperature inhibition of bacterial metabolism. The pH of the whey should never be below pH=6 before it is concentrated.
Whev - fat removal
The whey that has been collected is first pumped at 38°C in a centrifugal separator to take out excess fat (Alfa-Laval MHMRPX-214TGV) 30 that was present during cheese production. The amount of fat is reduced to a level of 0.06% in the resulting whey. The Ph in our examples was at 6.48. The whey is then chilled to 4°C and stored till ultrafiltration (U.F.) is
9
WO 95/17830 PCT/CA94/00726
carried out. The temperature is then raised at 40 °C for the Ultrafiltration (using Romicon cartridge with a cut off of 50,000 Dalton). If necessary it can be given a second pasteurization as shown in Figure 1 under conditions similar to the pasteurization previously described.
Whev - pasteurization
In our examples, whey was pasteurized. This heat treatment was mainly applied to control the activity of lactic acid bacteria that was previously added to milk. It also serve to control post pasteurization contamination that could occur during cheese making.
Ultrafiltration
During ultrafiltration the retentate is submitted to diafiltration by adding water so as to reduce the lactose level (4.6%) so that the retentate from ultrafiltration contains less than 1% of lactose. The retentate following completion of ultrafiltration has a total solids of 19-20%.
The conditions of ultrafiltration are set forth below in Table 1.
TABLE 1
TEMPERATURE < 40°C
Transmembrane pressure (TMP) 1.0 BAR TANGENTIAL
VELOCITY >7m/s
Concentration factor (CF) 29
FLUX 24.5 l/m2/h
The membrane flux increases 2-2Vi per degree centigrade, giving a similar increase in capacity of a plant. This means that without special 25 reasons for operations at low temperature, it is an advantage in conventional practice to operate at as high a temperature as possible.
The temperature utilized in most other commercial methods during this procedure is 50°C. This level of temperature facilitates a higher flux through the membranes hence more retentate production per unit of time and per unit 30 of membrane. In our method, the draw-back of less production per unit of membrane is compensated by increasing the membrane surface.
The objective of not exceeding 40°C is obtained throughout the system
m
by fine tuning the points of input and output in the system so as to avoid a heat producing unbalance between the two. After ultrafiltration the temperature of the retentate is then lowered to 4°C and kept at that temperature till freeze drying is started.
The composition of the retentate is about 19-20% total solids. A
typical composition is:
Fat 2.09%
True protein 15.91
Non protein nitrogen 0.04
Lactose 0.84
Ash 1.0
Total Solids 19.88%
Vitamins and flavours may, if desired, be added to the retentate after 15 ultrafiltration. The retentate may be regarded as a final product and sold in liquid form. Alternatively, the retentate can be concentrated to provide a dry product as described below.
Whev - drying
Concentration to produce a dry product by lyophilization (freeze 20 drying) is performed at temperatures under 0°C for 15 to 18 hours. This does not denature the thermolabile proteins.
In our examples, the retentate was subjected to a blast freeze at -25°C before entering in the freeze dryer. The temperature of the condenser were maintained at -50°C during the 17 hours of the freeze drying period. 25 The microbial counts of the retentate compare favourably with standards applicable to conventional pasteurization. These standards differ in each jurisdiction. As an example, the Province of Quebec, Canada, requires that total bacteria count (aerobic mesophiles (32 °C) be maintained below 50,000 (log 4.69), both in the factory and in the final product in the case of 30 powdered milk products. Coliforms are to be below 10. The Province of
Quebec has a standard of a bacteria count of 25,000 (log 4.39) and a coliform count of 5 in the factory for milk products that have not been pasteurized or
11
fermented.
Table 2 illustrates the composition of whey protein concentrate powder obtained using the principles described above.
Certain factors cannot be controlled during normal production of whey concentrate powders. Seasonal variation of milk composition and bacterial metabolism that occurs in milk at each step of the cheese making process will be mainly responsible for the differences observed in the composition of the concentrate. However, the practice of the principles of this invention may be expected to produce a consistently high level of thermolabile proteins such as serum albumin and to avoid substantial loss of the glutamylcysteine groups in the whey proteins.
12
TABLE 2
COMPOSITION OF WHEY PROTEIN CONCENTRATE POWDER
Example 1
Example 2
Example 3
PROTEIN (%)
77.5
77.04
78.08
a Lactalbumin (%)
23.68
23.85
22.20
0 Lactoglobulin (%)
59.90
60.37
61.40
Serum Albumin (%)
11.11
9.67
11.35
Others (%) (immunoglobulin, lactoferrin, etc.)
.31
6.14
.05
FAT (%)
.
9.76
8.12
LACTOSE (%)
4.25
4.6
4.9
MOISTURE (%) (maximum)
4. .
4.
4.
OTHER NUTRIENTS (mg/g)
Ca
.06
4.78
4.84
Mg
0.66
0.65
0.66
Cu
3.05
2.48
3.05
Zn
8.76
7.12
9.35
Na
4.23
4.67
3.53
K
6.45
6.35
4.05
CI
.82
11.70
9.59
MICROBIOLOGY
Salmonella (/100g)
No growth
No growth
No growth
Coli (/100g)
<50
<50
<50
Staphyloccoccus (/g)
<50
<50
<50
Total count (/g)
<10000
<10000
<10000
NITROGEN SOLUBILITY INDEX
99%
98.9%
99.5%
PCT/CAO4/00726
The protein composition and solubility of the final product in powder form after concentration by ultrafiltration and lyophilization (Table 2) meets the requirements previously identified by us as essential for the development of immunoenhancing activity and tissue GSH promotion: serum albumin concentration around 9% and minimal degree of denaturation. In each of the examples the serum albumin is over 9.596. In Table 3 and Table 4 are presented for comparison the concentrations of serum albumin in current commercially available W.P.C.'s and the nitrogen solubility index determined by De Wit in some W.P.C. products.
TABLE 3
WHEY PROTEIN CONCENTRATE Pre mod*
Alacen 855* Lacprodan-80* Sapro*
Savorpor-75* Bioisolate*
Promix*
Mean ± SD *trade-marks
BOVINE SERUM ALBUMIN in % of Total Whey Protein 4 ± 1 4 ± 1 4.8 ± 2 4 ± 0.1
4 ± 1
± 1 3 ± 1
14
0
TABLE 4
WHEY PROTEIN
CONCENTRATE
NSI at dH 4.6
Normal UF WPC
83 %
Neutral UF-DF-WPC
78%
Acid UF-DF-WPC
42 %
De-fatted UF WPC
91 %
Spherosil* 'OMA'
79%
Spherosil* 'S* WPC
%
Vistec* WPC
%
Demin. de-lact. WPC
72 %
From De Wit J.N. et al
Neth. Milk Dairy I. 37 (1983) pp. 37-49
The process of this invention therefore provides a practical procedure 15 for making undenatured whey protein concentrate. Furthermore it has the advantage of using a by-product of cheese production which is otherwise considered to be a troublesome waste product, and a potential pollutant. It should solve what was until now a continuing financial problem for the dairy industry responsible for the disposal of this major water pollutant. 20 In conclusion, it is the objective of this invention to preserve intact the conformation of the labile whey proteins in the W.P.C. This objective of leniency is obtained through several inter-dependent steps involving temperature, ions content, ultrafiltration flux and drying techniques.
* Trademarks
WO 95/17830 PCT/CA94/00726
REFERENCES (which are incorporated by reference in their entirety)
1. Bounous G., Konshavn P.A.C. "Influence of Dietary Proteins on the Immune System of Mice". J.Nutr. 112, 1747, 1982.; 5 2. Bounous G., Gold P. "The Biological Activity of Undenatured Dietary
Whey Proteins: Role of Glutathione" Clin.Invest.Med. 14: 296-309, 1991.
3. Bounous G., Batist. G; Gold P. : "Immunoenhancing Property of Dietary Whey Protein in Mice: Role of Glutathione". Clin. Invest. Med. 12: 154-61, 1989.
4. Brown R.T. "Milk Coagulation and Protein Denaturation in
'Fundamentals of Dairy Chemistry'", 3rd Edition, N.P. Wong (Ed) Van Nostrand Reynold C. (Publ.) New York, 1988, pp.583-607.
. Fauquant, J.; Maubois, J.L.; Pierre, A. "Microfiltration au lait sur Membrane Minerale" Tech.Lait 1028, 21-23, 1988.
6. AOAC 1980, "Official Methods of Analysis" 13 Edition Association of
Official Analytical Chemists, Washington, D.C.
7. AOAC 1985, "Official and Tentative Methods of the American Oil Chemist Society, Official Methods", Ball-65, Revised Edition.
8. Shimada K, Matsushita S.J. Agric. Food Chem. 1981, 29, 15-20.
9. Kosikowski F. (1977), Cheese and Fermented milk Foods, 2d Edition,
F.V. Kosikowski & Associates, N.Y.
16
. Wong N.P., Jeimess R., Kenney M; Marth E.H. 1988, Fundamentals of Dairy Chemistry, 3d Edition, Van Nostrand Reinbold, N.Y.
11. Haurowitz F. "Albumins, globulins and other proteins" in The Chemistry and Functions of Proteins, (Academic Press NY 1963).
17
Claims (20)
1. A process for producing an undenatured whey protein concentrate having a serum albumin content of about 9% or more as a by-product of a process for making cheese comprising the following steps: (1) cold standardization of the fat content in milk; (2) pasteurization prior to cheese making under conditions that will avoid any substantial denaturing of the protein in the milk; (3) chilling preliminary to cheese production without the addition of calcium ions, to a temperature of about 30°C; (4) making cheese curd and whey at a temperature not greater than about 40°C; (5) separating the curd from the whey; (6) removal of excess fat from the whey; (7) pasteurization, if needed, at a high temperature for a time short enough to avoid any substantial denaturing of the protein in the milk; (8) ultrafiltration at a temperature close to but not substantially in excess of 40°C to provide a retentate; the pH being maintained at not less than 6 through steps (1) to (8).
2. A process as in claim 1, in which the retentate is dried at a temperature and time that will not denature the protein.
3. A process as in claim 1 in which cold sta^c|^i|$^^gfe& temperature of about 4°C. $ 1 $98 of No* Zeatew* 19 2 7 8 0 1 8 -
4. A process as in claim 1 in which pasteurization of steps (2) and (7) is at temperatures of about 70°C - 75°C for less than 20 seconds.
5. A process as in claim 1 in which pasteurization prior to cheese making is immediately followed by flash cooling to a temperature of approximately 30°C. 5
6. A process as in Claim 1, in which ultrafiltration is accompanied by diafiltration to reduce the lactose level in the retentate to less than 1%.
7. A process as in claim 2, in which the retentate is concentrated by lyophilization.
8. A process as in claim 1, in which no additional whey is collected during 10 final shaping and pressing of the curd.
9. A process as in claim 1, in which the retentate is freeze dried.
10. A process as in claim 1 f in which the cheese curd is cheddar cheese curd.
11. A process as in claim 1 in which the addition of calcium chloride to the milk is avoided. 15
12. A process as in claim 1, in which the retentate from ultrafiltite(Mi^iBra^n&lDffice liquid product having a solids content of about 19-20%. 0 9 FFB 1998 of New Zealand
13. A process for producing an undenatured whey protein concentrate, which concentrate contains substantially all thermolabile whey proteins of the source milk with glutamylcysteine groups and disulfide bonds, in an amount effective to replenish depleted 20 intracellular glutathione, enhance systemic humoral immune response and exert anticancer effects, comprising cold standardization of milk, pasteurization, the formation of curd and whey, separation of the whey, filtering concentrating and drying the whey under 20 2780j8 conditions of time and temperature that will avoid substantial loss of said glutamylcysteine groups and at a pH of not less than 6 prior to concentration.
14. A process as in claim 13, wherein the whey protein concentrate comprises a substantially undenatured whey protein isolate mixture containing bovine serum albumin, a-lactalbumin and lactoferrin proteins, which are cystine rich, in a biologically effective amount to replenish depleted cellular glutathione (GSH), enhance the immune response and exert anti-cancer effects.
15. A process as in claim 13 or 14 in which the addition of a calcium compound that would cause denaturation of serum albumin is avoided.
16. A process as in any one of claims 13 to 15 in which the whey is separated in a prepressing operator, prior to shaping and final pressing of the curd.
17. A process as in any one of claims 13 to 16 in which the undenatured whey protein concentrate has a serum albumin concentration of at least 9%.
18. A process as in any one of claims 1 to 17 in which the undenatured whey protein concentrate has a serum albumin content of at least 9.5%.
19. A process as in claim 7 in which the whey protein concentrate powder has a lactose level of 4 to 5%.
20. A process as claimed in any one of the preceding claims substantially as herein described. lim?«&SWwr5 Office 0 9 FFR 1998 of New Zealand
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17563793A | 1993-12-30 | 1993-12-30 | |
US31590494A | 1994-09-30 | 1994-09-30 | |
PCT/CA1994/000726 WO1995017830A1 (en) | 1993-12-30 | 1994-12-23 | Process for making undenatured whey protein concentrate |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ278018A true NZ278018A (en) | 1998-04-27 |
Family
ID=26871418
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ278018A NZ278018A (en) | 1993-12-30 | 1994-12-23 | Producing undenatured whey protein concentrate |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0739168A1 (en) |
JP (1) | JPH09507029A (en) |
AU (1) | AU692508B2 (en) |
CA (1) | CA2176946C (en) |
NZ (1) | NZ278018A (en) |
PL (1) | PL315195A1 (en) |
TW (1) | TW267095B (en) |
WO (1) | WO1995017830A1 (en) |
ZA (1) | ZA949789B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6720018B2 (en) | 2000-04-21 | 2004-04-13 | Snow Brand Milk Products Co., Ltd. | Method for producing milk calcium composition |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2165937A1 (en) * | 1995-05-09 | 1996-11-10 | Immunotec Research Corporation Ltd. | Process for producing an undenatured whey protein concentrate |
AT8032U1 (en) * | 2004-07-02 | 2006-01-15 | Landfrisch Molkerei Registrier | METHOD FOR PRODUCING A PROTEIN CONCENTRATE FROM SAUCE BALM AND USE OF SUCH PROTEIN CONCENTRATE |
WO2009113845A1 (en) | 2008-03-12 | 2009-09-17 | N.V. Nutricia | High protein liquid enteral nutritional composition |
US8409651B2 (en) | 2007-12-05 | 2013-04-02 | N. V. Nutricia | High energy liquid enteral nutritional composition |
ITRM20120412A1 (en) * | 2012-08-13 | 2014-02-14 | Biontologia S R L Lab | METHOD FOR THE PREPARATION OF A SERCERAL PROTEIN CONCENTRATE. |
JP6749774B2 (en) * | 2016-03-24 | 2020-09-02 | 森永乳業株式会社 | Method for producing liquid fermented milk |
CN111620937A (en) * | 2020-03-09 | 2020-09-04 | 烟台双塔食品股份有限公司 | Method for extracting high-purity albumin |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4112123A (en) * | 1976-07-21 | 1978-09-05 | Beatrice Foods Co. | Nutritionally balanced single food composition and method of production |
CH627079A5 (en) * | 1977-04-15 | 1981-12-31 | Nestle Sa | Process for preparing a protein concentrate containing immunological factors of milk origin |
FR2459619B1 (en) * | 1979-06-26 | 1983-07-29 | Agronomique Inst Nat Rech | PROCESS FOR OBTAINING FROM LACTOSERUM, A PRODUCT ENRICHED IN ALPHA-LACTALBUMIN AND APPLICATIONS OF SAID PROCESS |
CA1338682C (en) * | 1988-12-23 | 1996-10-29 | Gustavo Bounous | Biologically active undenatured whey protein concentrate as food supplement |
-
1994
- 1994-12-08 ZA ZA949789A patent/ZA949789B/en unknown
- 1994-12-22 TW TW083112060A patent/TW267095B/zh active
- 1994-12-23 CA CA002176946A patent/CA2176946C/en not_active Expired - Lifetime
- 1994-12-23 PL PL94315195A patent/PL315195A1/en unknown
- 1994-12-23 JP JP7517704A patent/JPH09507029A/en active Pending
- 1994-12-23 WO PCT/CA1994/000726 patent/WO1995017830A1/en not_active Application Discontinuation
- 1994-12-23 NZ NZ278018A patent/NZ278018A/en not_active IP Right Cessation
- 1994-12-23 EP EP95905493A patent/EP0739168A1/en not_active Ceased
- 1994-12-23 AU AU14097/95A patent/AU692508B2/en not_active Expired
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6720018B2 (en) | 2000-04-21 | 2004-04-13 | Snow Brand Milk Products Co., Ltd. | Method for producing milk calcium composition |
Also Published As
Publication number | Publication date |
---|---|
CA2176946C (en) | 2006-02-07 |
JPH09507029A (en) | 1997-07-15 |
ZA949789B (en) | 1995-10-25 |
CA2176946A1 (en) | 1995-07-06 |
AU692508B2 (en) | 1998-06-11 |
WO1995017830A1 (en) | 1995-07-06 |
EP0739168A1 (en) | 1996-10-30 |
PL315195A1 (en) | 1996-10-14 |
AU1409795A (en) | 1995-07-17 |
TW267095B (en) | 1996-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100588922B1 (en) | Method for producing cheese and cheese products | |
US11219225B2 (en) | Methods for casein production | |
KR101998891B1 (en) | Cheese and preparing the same | |
EP3232796B1 (en) | Yoghurt with native whey proteins and processes for production thereof | |
EP1364583B1 (en) | Dairy products with reduced average particle size | |
RU2352129C2 (en) | Cream cheese, manufactured of whey proteins polymers | |
US20030077357A1 (en) | Microfiltration of skim milk for cheese making and whey proteins | |
EP0008242B1 (en) | A process for treating a protein source and a food product having a treated protein source prepared by the process | |
WO1994013148A1 (en) | Process for producing an undernatured whey protein concentrate | |
CN115103596B (en) | High protein yoghurt product and production method thereof | |
AU692508B2 (en) | Process for making undenatured whey protein concentrate | |
CA3150208A1 (en) | Method of making french-type goat cheese | |
WO1996035336A1 (en) | A process for producing an undenatured whey protein concentrate | |
RU2535876C2 (en) | Milk processing method and product produced by this method | |
AU2006233196B2 (en) | Enriched milk products | |
García-Garibay et al. | Whey proteins: bioengineering and health | |
WO2022136575A1 (en) | Method of preparing cheese curds | |
Metwalli | Effect of heat denatured whey proteins on the quality of yoghurt | |
CN117281175A (en) | Whey cheese and preparation method thereof | |
KR20210055266A (en) | Method for producing cheese and cheese goods | |
MXPA01004551A (en) | Method for producing cheese and cheese products |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RENW | Renewal (renewal fees accepted) | ||
RENW | Renewal (renewal fees accepted) | ||
RENW | Renewal (renewal fees accepted) | ||
EXPY | Patent expired |